Halozyme Therapeutics | HALO - Gross Profit On Sales


Halozyme Therapeutics reported $297.47M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
Amgen USD 6.89B 415M Dec/2025
Baxter International USD 891M 314M Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cytokinetics USD 19.2M 1.44M Mar/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 243M 48M Mar/2026
MannKind USD 68.33M 9.98M Mar/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024